2018 Q4 Form 10-K Financial Statement

#000143774919005538 Filed on March 22, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $17.56M $67.14M $18.89M
YoY Change -7.02% -5.54% 12.11%
Cost Of Revenue $7.590M $27.57M $6.460M
YoY Change 17.49% 50.1% 17.67%
Gross Profit $9.973M $39.57M $12.44M
YoY Change -19.83% -8.74% 9.51%
Gross Profit Margin 56.78% 58.94% 65.85%
Selling, General & Admin $8.610M $34.51M $10.17M
YoY Change -15.34% -1.43% 3.25%
% of Gross Profit 86.33% 87.2% 81.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.237M $6.659M $1.480M
YoY Change -16.42% -4.37% -86.23%
% of Gross Profit 12.4% 16.83% 11.9%
Operating Expenses $9.847M $39.16M $11.64M
YoY Change -15.4% -17.0% 4.77%
Operating Profit $126.0K $415.0K $800.0K
YoY Change -84.25% -110.89% 220.0%
Interest Expense -$439.0K $1.420M -$320.0K
YoY Change 37.19% 6.61% -3.03%
% of Operating Profit -348.41% 342.17% -40.0%
Other Income/Expense, Net -$18.00K -$1.457M $0.00
YoY Change 0.83% -100.0%
Pretax Income -$331.0K -$1.042M -$1.630M
YoY Change -79.69% -80.18% 103.75%
Income Tax -$56.00K $53.00K -$640.0K
% Of Pretax Income
Net Earnings -$275.0K -$1.095M -$17.99M
YoY Change -98.47% -94.71% 3727.66%
Net Earnings / Revenue -1.57% -1.63% -95.24%
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$14.07K -$0.05 -$789.7K
COMMON SHARES
Basic Shares Outstanding 21.42M 22.78M shares
Diluted Shares Outstanding 21.42M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.318M $4.318M $3.500M
YoY Change 23.37% 24.47% 2.94%
Cash & Equivalents $4.318M $4.318M $3.469M
Short-Term Investments
Other Short-Term Assets $1.372M $1.372M $1.150M
YoY Change 19.3% 19.3% 21.18%
Inventory $2.254M $2.254M $1.764M
Prepaid Expenses
Receivables $9.593M $9.593M $11.28M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.54M $17.54M $17.67M
YoY Change -0.74% -0.74% -14.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.445M $26.53M $1.633M
YoY Change -11.51% -0.13% -18.23%
Goodwill
YoY Change
Intangibles $19.87M $24.51M
YoY Change -18.96% -21.53%
Long-Term Investments
YoY Change
Other Assets $137.0K $137.0K $131.0K
YoY Change 4.58% 4.58% -41.78%
Total Long-Term Assets $46.54M $46.54M $51.21M
YoY Change -9.13% -9.13% -32.23%
TOTAL ASSETS
Total Short-Term Assets $17.54M $17.54M $17.67M
Total Long-Term Assets $46.54M $46.54M $51.21M
Total Assets $64.07M $64.07M $68.88M
YoY Change -6.98% -6.98% -28.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.091M $7.091M $5.516M
YoY Change 28.55% 28.55% 3.78%
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.903M $4.936M $3.039M
YoY Change 61.34% 39.28% -42.81%
Total Short-Term Liabilities $14.79M $14.79M $12.47M
YoY Change 18.57% 18.57% -24.12%
LONG-TERM LIABILITIES
Long-Term Debt $28.84M $28.84M $25.35M
YoY Change 13.77% 13.62% -4.61%
Other Long-Term Liabilities $0.00 $7.000K
YoY Change -100.0% -89.39%
Total Long-Term Liabilities $43.63M $28.84M $37.93M
YoY Change 15.04% 13.59% 29.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.79M $14.79M $12.47M
Total Long-Term Liabilities $43.63M $28.84M $37.93M
Total Liabilities $43.63M $43.63M $37.93M
YoY Change 15.04% 15.04% -16.92%
SHAREHOLDERS EQUITY
Retained Earnings -$62.73M -$61.63M
YoY Change 1.78% 49.81%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.44M $20.44M $30.95M
YoY Change
Total Liabilities & Shareholders Equity $64.07M $64.07M $68.88M
YoY Change -6.98% -6.98% -28.51%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$275.0K -$1.095M -$17.99M
YoY Change -98.47% -94.71% 3727.66%
Depreciation, Depletion And Amortization $1.237M $6.659M $1.480M
YoY Change -16.42% -4.37% -86.23%
Cash From Operating Activities $3.181M $11.39M $3.620M
YoY Change -12.13% 47.59% -13.19%
INVESTING ACTIVITIES
Capital Expenditures -$3.782M $281.0K -$120.0K
YoY Change 3051.67% 170.19% -93.33%
Acquisitions
YoY Change
Other Investing Activities $975.0K $3.319M $350.0K
YoY Change 178.57% -14.15% -69.3%
Cash From Investing Activities -$2.807M -$4.984M $230.0K
YoY Change -1320.43% -642.92% -135.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.00K -5.558M -1.180M
YoY Change -105.25% -35.11% -0.84%
NET CHANGE
Cash From Operating Activities 3.181M 11.39M 3.620M
Cash From Investing Activities -2.807M -4.984M 230.0K
Cash From Financing Activities 62.00K -5.558M -1.180M
Net Change In Cash 436.0K 849.0K 2.670M
YoY Change -83.67% 1095.77% 14.59%
FREE CASH FLOW
Cash From Operating Activities $3.181M $11.39M $3.620M
Capital Expenditures -$3.782M $281.0K -$120.0K
Free Cash Flow $6.963M $11.11M $3.740M
YoY Change 86.18% 45.92% -37.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19577024
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q2 dei Entity Public Float
EntityPublicFloat
60990253
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Current
CapitalAndOperatingLeasesFutureMinimumPaymentsCurrent
1899000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due
CapitalAndOperatingLeasesFutureMinimumPaymentsDue
12378000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Five Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFiveYears
1040000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Four Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFourYears
1016000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Three Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInThreeYears
1107000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Two Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInTwoYears
1717000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due Thereafter
CapitalAndOperatingLeasesFutureMinimumPaymentsDueThereafter
5599000
CY2018 infu Concentration Risk Percentage Of Raw Material Purchases From Suppliers Minimum Threshold
ConcentrationRiskPercentageOfRawMaterialPurchasesFromSuppliersMinimumThreshold
0.1
CY2018 infu Cost Of Revenues Pump Depreciation Sales And Disposals
CostOfRevenuesPumpDepreciationSalesAndDisposals
8788000
CY2017 infu Cost Of Revenues Pump Depreciation Sales And Disposals
CostOfRevenuesPumpDepreciationSalesAndDisposals
9349000
CY2018 infu Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
CY2017 infu Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
11435000
CY2018 infu Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
65000
CY2017 infu Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
CY2018 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
6200000
CY2017 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
6500000
CY2018 infu Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.094
CY2017 infu Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.083
CY2014Q2 infu Employee Stock Ownership Plan Esop Purchase Per Employee Maximum
EmployeeStockOwnershipPlanESOPPurchasePerEmployeeMaximum
25000
CY2014Q2 infu Employee Stock Purchase Plan Discount Rate
EmployeeStockPurchasePlanDiscountRate
0.15
CY2018 infu Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
2.45
CY2017 infu Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
2.21
CY2018Q4 infu Longterm Debt Maturities Repayments Of Principal In Year Five And Thereafter
LongtermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
898000
CY2018Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1601000
CY2017Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1567000
CY2018Q4 infu Medical Equipment Held For Sale Or Rental Reserves
MedicalEquipmentHeldForSaleOrRentalReserves
500000
CY2017Q4 infu Medical Equipment Held For Sale Or Rental Reserves
MedicalEquipmentHeldForSaleOrRentalReserves
500000
CY2018Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
23488000
CY2017Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
23369000
CY2018Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
37411000
CY2017Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
34077000
CY2018Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
61429000
CY2017Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
57928000
CY2018Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
530000
CY2017Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
482000
CY2018 infu Medical Equipment In Rental Services Useful Life
MedicalEquipmentInRentalServicesUsefulLife
P7Y
CY2018Q4 infu Medical Equipment Net
MedicalEquipmentNet
25089000
CY2017Q4 infu Medical Equipment Net
MedicalEquipmentNet
24936000
CY2018 infu Net Operating Loss Carryforwards Limitation On Use
NetOperatingLossCarryforwardsLimitationOnUse
1800000
CY2018Q4 infu Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2018Q4 infu Number Of Operating Locations
NumberOfOperatingLocations
5
CY2018 infu Percentage Of Reduction In Shares Outstanding From Repurchases
PercentageOfReductionInSharesOutstandingFromRepurchases
0.15
CY2018 infu Provision For Doubtful Accounts Netted Against General And Administrative Expense
ProvisionForDoubtfulAccountsNettedAgainstGeneralAndAdministrativeExpense
CY2018Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Two
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearTwo
38000
CY2018Q4 infu Remaining Preownership Net Operating Loss Carryforwards
RemainingPreownershipNetOperatingLossCarryforwards
4700000
CY2018Q4 infu Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance
251430
CY2018Q3 infu Stock Repurchase Agreement Shares To Be Repurchased
StockRepurchaseAgreementSharesToBeRepurchased
2800000
CY2018 infu Third Party Payor Provision For Doubtful Accounts
ThirdPartyPayorProvisionForDoubtfulAccounts
CY2017 infu Third Party Payor Provision For Doubtful Accounts
ThirdPartyPayorProvisionForDoubtfulAccounts
5615000
CY2018Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
38000
CY2017Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
28000
CY2018Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
76000
CY2017Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
92000
CY2018Q4 infu Unamortized Value Of Debt Issuance Costs Principal Current
UnamortizedValueOfDebtIssuanceCostsPrincipalCurrent
38000
CY2018Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Five And Thereafter
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFiveAndThereafter
CY2018Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Four
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFour
CY2018Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Three
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearThree
38000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7091000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5516000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9593000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11284000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4609000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4496000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83167000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
92584000
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
58000
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
70000
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
131000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
91000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
682000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
957000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
33000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4649000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5560000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
993000
CY2018Q4 us-gaap Assets
Assets
64073000
CY2017Q4 us-gaap Assets
Assets
68881000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17537000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
17667000
CY2018 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; font-weight: bold;">Basis of Presentation and Nature of Operations</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the &#x201c;Company&#x201d;) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc., which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc., which is an operating subsidiary of the Company, is ISO certified.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company&#x2019;s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company&#x2019;s pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supply more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the ambulatory pumps purchased by the Company. The Company has a supply agreement in place with each of these suppliers. Certain &#x201c;spot&#x201d; purchases are made on the open market subject to individual negotiation.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for, oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company&#x2019;s ambulatory infusion pump management service.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).</div></div>
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
998000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
549000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
33000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
505000
CY2018 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2017 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
137000
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
33000
CY2018 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2300000
CY2017 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
3100000
CY2018Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
0
CY2017Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
200000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3469000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3398000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4318000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
849000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
71000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23095513
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22978398
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19577024
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22780738
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party reimbursement, it is possible that management&#x2019;s estimates could change in the near term, which could have a material impact on the Company&#x2019;s results of operations and cash flows.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> our largest contracted payor was a national payor which accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%</div> of our net revenues from our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor Oncology Business for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4%</div> of our total net revenues for each of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">We also contract with various other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payor noted above, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> other single payor represented more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7%</div> of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor net revenue.</div></div></div></div></div></div></div></div>
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19332000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18367000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
216000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-73000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
31000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
88000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
84000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
45000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-62000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
13830000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-62000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15389000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1560000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11435000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11370000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
62000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
62000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
600000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.06
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.022
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31058000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26409000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
600000
CY2018 us-gaap Depreciation
Depreciation
6659000
CY2017 us-gaap Depreciation
Depreciation
6963000
CY2018 us-gaap Depreciation Nonproduction
DepreciationNonproduction
400000
CY2017 us-gaap Depreciation Nonproduction
DepreciationNonproduction
500000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.05
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-2.939
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2.175
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.14
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046
CY2018 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
33874
CY2017 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
49150
CY2014Q2 us-gaap Employee Stock Ownership Plan Esop Shares Contributed To Esop
EmployeeStockOwnershipPlanESOPSharesContributedToESOP
200000
CY2018 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-62000
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
13757000
CY2018Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.035
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2649000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4402000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
548000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2051000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3930000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4285000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1340000
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1662000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24847000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25226000
CY2018 us-gaap Gross Profit
GrossProfit
39018000
CY2017 us-gaap Gross Profit
GrossProfit
43361000
CY2018Q4 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1000000
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
434000
CY2017 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
207000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1138000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5419000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1042000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5257000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
96000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
162000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1042000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5257000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15450000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
159000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
139000
CY2018 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
183000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2017 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-352000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4413000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5344000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
490000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-402000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
222000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
201000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-119000
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2018Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
50923000
CY2017Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
50923000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19865000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24514000
CY2018 us-gaap Interest Expense
InterestExpense
1420000
CY2017 us-gaap Interest Expense
InterestExpense
1332000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1383000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
1200000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2254000
CY2017Q4 us-gaap Inventory Net
InventoryNet
1764000
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64073000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68881000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14790000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12474000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
43632000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
37928000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
33745000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
28391000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4903000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3039000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
512000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
22145000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5287000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4903000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10554000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9992000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28842000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25352000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5558000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8565000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4984000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
918000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11391000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7718000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1095000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-20707000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1457000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1445000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Operating Expenses
OperatingExpenses
38603000
CY2017 us-gaap Operating Expenses
OperatingExpenses
47173000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
415000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-3812000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
12345000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1866000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1040000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1016000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1107000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1717000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5599000
CY2018 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
56584000
CY2017 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
61085000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1372000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1150000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2763000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3414000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-113000
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10395000
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
27000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
38000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
70000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
58000
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
192000
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
8022000
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2652000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
104000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Reclassifications</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effect on reported (loss) income, overall cash flows, total assets, total liabilities or stockholders&#x2019; equity as previously reported.</div></div></div></div></div></div></div></div>
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11162000
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
28866000
CY2018 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3319000
CY2017 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3866000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
91000
CY2017 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
131000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6054000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6129000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1445000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1633000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6104000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5641000
CY2018 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
6319000
CY2017 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
37466000
CY2018 us-gaap Restricted Stock Expense
RestrictedStockExpense
78000
CY2017 us-gaap Restricted Stock Expense
RestrictedStockExpense
48000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62728000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61633000
CY2018 us-gaap Revenues
Revenues
67138000
CY2017 us-gaap Revenues
Revenues
71077000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9107000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9779000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
957000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
682000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.09
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
350000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y302D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y339D
CY2018 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000
CY2017 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000
CY2018 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
84000
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1605000
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
43433
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
68958
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
CY2018 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
879000
CY2017 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
634000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
50689000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
30953000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
20441000
CY2018 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3300000
CY2017 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10395000
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
114000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
120000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Use</div><div style="display: inline; font-style: italic;"> of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, accounts receivable and allowance for doubtful accounts, sales return allowances, inventory reserves, long lived assets, intangible assets valuations and income tax valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div>
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21417628
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22739651
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21417628
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22739651
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21417628
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22739651

Files In Submission

Name View Source Status
0001437749-19-005538-index-headers.html Edgar Link pending
0001437749-19-005538-index.html Edgar Link pending
0001437749-19-005538.txt Edgar Link pending
0001437749-19-005538-xbrl.zip Edgar Link pending
ex_137520.htm Edgar Link pending
ex_137521.htm Edgar Link pending
ex_137522.htm Edgar Link pending
ex_137523.htm Edgar Link pending
ex_137524.htm Edgar Link pending
ex_137525.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
infu-20181231.xml Edgar Link completed
infu-20181231.xsd Edgar Link pending
infu-20181231_cal.xml Edgar Link unprocessable
infu-20181231_def.xml Edgar Link unprocessable
infu-20181231_lab.xml Edgar Link unprocessable
infu-20181231_pre.xml Edgar Link unprocessable
infu.jpg Edgar Link pending
infu20181231_10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending